Protected: Biden and biotech: Science first

Posted on January 21, 2021 By News Team

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. biotech-today.com is a wholly-owned subsidiary of Maynard Communication Limited.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

error: Content is protected !!

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

GSK, German Merck’s $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer